Why carry out this analysis?
|
Plaque psoriasis is associated with significant physical and psychological impairment. Although effective treatment of psoriasis has been shown to improve quality of life (QoL), loss of clinical response over time has been observed for some biologics. |
Treatment with certolizumab pegol has been shown to result in sustained and durable improvements in the signs and symptoms of moderate-to-severe plaque psoriasis. |
It is important to understand whether improvements in patients’ health-related QoL were sustained throughout long-term treatment. |
What was learned from this analysis?
|
Treatment with certolizumab pegol was associated with sustained and tangible improvements in patients’ health-related quality of life over 3 years, with increased work productivity, decreased pain and improved ability to engage in daily activities, as observed across multiple patient-reported outcomes. |
These improvements were consistent across patient subgroups regardless of sex, psoriatic arthritis status and prior exposure to biologics. |
Digital Features
Introduction
Methods
Patients and Study Designs
Outcomes
Statistical Analyses
Results
Patient Disposition and Baseline Characteristics
CZP 200 mg Q2W (N = 186) | CZP 400 mg Q2W (N = 175) | All CZP (N = 361) | Placebo (N = 100) | |
---|---|---|---|---|
Age (years), mean ± SD | 45.6 ± 13.2 | 45.0 ± 12.9 | 45.3 ± 13.0 | 45.7 ± 13.8 |
Caucasian, n (%) | 173 (93.0) | 160 (91.4) | 333 (92.2) | 89 (89.0) |
Male, n (%) | 125 (67.2) | 103 (58.9) | 228 (63.2) | 61 (61.0) |
Concurrent PsA (self-reported), n (%) | 32 (17.2) | 41 (23.4) | 73 (20.2) | 13 (13.0) |
Prior biologic therapy, n (%) | 62 (33.3) | 59 (33.7) | 121 (33.5) | 29 (29.0) |
Disease duration (years), mean ± SD | 17.7 ± 12.9 | 18.5 ± 12.6 | 18.1 ± 12.7 | 16.9 ± 12.6 |
Weight (kg), mean ± SD | 95.1 ± 23.4 | 92.0 ± 24.8 | 93.6 ± 24.1 | 91.3 ± 23.4 |
PASI, mean ± SD | 19.2 ± 7.2 | 19.6 ± 7.3 | 19.4 ± 7.3 | 18.6 ± 6.6 |
BSA affected (%), mean ± SD | 23.5 ± 14.9 | 23.6 ± 14.3 | 23.5 ± 14.6 | 23.1 ± 13.6 |
PGA, n (%) | ||||
3, moderate | 128 (68.8) | 126 (72.0) | 254 (70.4) | 72 (72.0) |
4, severe | 58 (31.2) | 49 (28.0) | 107 (29.6) | 28 (28.0) |
DLQI, mean ± SDa | 14.3 ± 7.4 | 13.7 ± 6.9 | 14.0 ± 7.1 | 13.4 ± 7.8 |
DLQI 0/1, n (%)a | 6 (3.3) | 1 (0.6) | 7 (2.0) | 2 (2.1) |
DLQI domain score of 0, n (%)b | ||||
Symptoms and Feelings | 2 (1.1) | 0 | 2 (0.6) | 2 (2.0) |
Daily Activities | 19 (10.3) | 12 (6.9) | 31 (8.7) | 11 (11.2) |
Leisure | 32 (17.4) | 36 (20.7) | 68 (19.0) | 26 (26.5) |
Work and School | 80 (43.5) | 70 (40.2) | 150 (41.9) | 48 (49.0) |
Personal Relationships | 54 (29.3) | 57 (32.8) | 111 (31.0) | 38 (38.8) |
Treatment | 61 (33.2) | 57 (32.8) | 118
(33.0) | 33 (33.7) |
EQ-5D-3L score of 1, n (%)a | ||||
Mobility | 123 (67.2) | 125 (72.3) | 248 (69.7) | 73 (75.3) |
Self-Care | 165 (90.2) | 153 (88.4) | 318 (89.3) | 91 (93.8) |
Usual Activities | 125 (68.3) | 115 (66.5) | 240 (67.4) | 65 (67.0) |
Pain/Discomfort | 33 (18.0) | 42 (24.3) | 75 (21.1) | 16 (16.5) |
Anxiety/Depression | 93 (50.8) | 87 (50.3) | 180 (50.6) | 50 (51.5) |
EQ VAS, mean ± SDa | 65.9 ± 22.7 | 66.1 ± 22.2 | 66.0 ± 22.4 | 66.2 ± 21.2 |
SF-36 PCS, mean ± SDa | 46.9 ± 9.3 | 48.5 ± 9.2 | 47.7 ± 9.3 | 47.7 ± 8.9 |
SF-36 MCS, mean ± SDa | 46.9 ± 11.0 | 45.5 ± 10.6 | 46.2 ± 10.8 | 45.3 ± 12.6 |
WPAI, mean ± SD | ||||
Absenteeismc | 4.5 ± 16.4 | 3.4 ± 13.9 | 4.0 ± 15.2 | 3.9 ± 10.1 |
Presenteeismc | 19.6 ± 25.6 | 19.6 ± 22.7 | 19.6 ± 24.2 | 18.8 ± 22.2 |
Work Impairmentc | 23.1 ± 29.2 | 22.1 ± 25.5 | 22.6 ± 27.4 | 20.8 ± 24.4 |
Activity Impairmenta | 33.0 ± 30.6 | 33.6 ± 28.8 | 33.3 ± 29.7 | 29.9 ± 25.8 |